J Korean Med Assoc.  2013 Feb;56(2):135-141. 10.5124/jkma.2013.56.2.135.

Biologic response modifiers

• Yoon HS
• Choi YS
• Lee EH

• KMID: 1785382
• DOI: http://doi.org/10.5124/jkma.2013.56.2.135

Abstract

Biotherapy, often called biological therapy or immunotherapy, aims at supporting and helping in the treatment of human disease without chemical drugs and invasive therapies, by restoring the natural immune system. It is also used to reduce certain side effects that may be caused by some treatments against cancer, autoimmune diseases, or other diseases. Biotherapy employs substances called biological response modifiers (BRMs). The term BRM is often used synonymously with the terms immunomodulator and immunostimulant. BRMs are agents that modify the host's response to pathogens with resultant beneficial prophylactic or therapeutic effects. The use of BRMs had rapidly expanded since the introduction of the first diagnostic antibodies. They are now employed in oncology, autoimmune diseases, inflammatory diseases, and transplantation medicine. BRMs used in biological therapy include interferones, interleukins, colony-stimulating factors, monoclonal antibodies, differentiation agents, tyrosine kinase inhibitor, tumor necrosis factor, vaccines, and nonspecific immunomodulating agents. BRMs are widely accepted in the treatment of certain types of cancer and rheumatoid arthritis, while others are being tested in research studies. This article reviewed the clinical use and side effects of BRMs in cancer and other diseases.

Keyword

Biologic response modifiers; Cancer; Rheumatic diseases

MeSH Terms

Antibodies
Antibodies, Monoclonal
Arthritis, Rheumatoid
Autoimmune Diseases
Biological Therapy
Colony-Stimulating Factors
Humans
Immune System
Immunologic Factors
Immunotherapy
Interferons
Interleukins
Protein-Tyrosine Kinases
Rheumatic Diseases
Transplants
Tumor Necrosis Factor-alpha
Vaccines
Antibodies
Antibodies, Monoclonal
Colony-Stimulating Factors
Immunologic Factors
Interferons
Interleukins
Protein-Tyrosine Kinases
Tumor Necrosis Factor-alpha
Vaccines

Reference

1. Mihich E. Historical overview of biologic response modifiers. Cancer Invest. 2000. 18:456–466.

2. Oettgen HF, Old LJ. De Vita VT, Hellman S, Rosenberg SA, editors. The history of cancer immunotherapy. Biologic therapy of cancer. 1991. Philadelphia: Lippincott;81–101.

3. Krauss J, Arndt M, Pfreundschuh M. Welschof M, Krauss J, editors. Application of recombinant antibodies in cancer patients. Recombinant antibodies for cancer therapy: methods and protocols. 2003. Totowa: Humana Press;27–53.

4. Kuroki M, Ueno A, Matsumoto H, Abe H, Li T, Imakiire T, Yamauchi Y, Uno K, Shirota K, Shibaguchi H, Kuroki M. Significance of tumor-associated antigens in the diagnosis and therapy of cancer: an overview. Anticancer Res. 2002. 22:4255–4264.

5. Weaver AL. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2004. 43:Suppl 3. iii17–iii23.

6. Osterman MT, Lichtenstein GR. Current and future anti-TNF therapy for inflammatory bowel disease. Curr Treat Options Gastroenterol. 2007. 10:195–207.

7. Park SH, Kim SK, Choe JY. Biologic agent for rheumatoid arthritis. Hanyang Med Rev. 2012. 32:68–76.

8. Hong MJ, Yoo WH. Biologic agents in rheumatic diseases. Korean J Med. 2012. 82:549–561.

9. Bisht M, Bist SS, Dhasmana DC. Biological response modifiers: current use and future prospects in cancer therapy. Indian J Cancer. 2010. 47:443–451.

10. Murthy TE, Janaki KS, Nagarjuna S, Sangeetha P, Sindhura S. Biological response modifiers. Int J Pharm Tech Res. 2010. 2:2152–2160.

11. Kuroki M, Miyamoto S, Morisaki T, Yotsumoto F, Shirasu N, Taniguchi Y, Soma G. Biological response modifiers used in cancer biotherapy. Anticancer Res. 2012. 32:2229–2233.

12. Tompkins WA. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J Interferon Cytokine Res. 1999. 19:817–828.

13. Hank JA, Gan J, Ryu H, Ostendorf A, Stauder MC, Sternberg A, Albertini M, Lo KM, Gillies SD, Eickhoff J, Sondel PM. Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma. Clin Cancer Res. 2009. 15:5923–5930.

14. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A. CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006. 355:2071–2084.

15. Kaushansky K. Thrombopoietin. N Engl J Med. 1998. 339:746–754.

16. Serebruany VL, Eisert C, Sabaeva E, Makarov L. Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations. Am J Ther. 2010. 17:68–74.

17. Grünhagen DJ, de Wilt JH, ten Hagen TL, Eggermont AM. Technology insight: utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Clin Pract Oncol. 2006. 3:94–103.

18. Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res. 2007. 13:1098–1106.

19. Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009. 49:1335–1374.

20. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005. 52:1227–1236.

21. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A. IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005. 64:1150–1157.

22. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000. 356:385–390.

23. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004. 50:2264–2272.

24. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA. Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005. 52:3279–3289.

25. Huynh N, Cervantes-Castaneda RA, Bhat P, Gallagher MJ, Foster CS. Biologic response modifier therapy for psoriatic ocular inflammatory disease. Ocul Immunol Inflamm. 2008. 16:89–93.

26. Rubinstein I. Human VIP-alpha: an emerging biologic response modifier to treat primary pulmonary hypertension. Expert Rev Cardiovasc Ther. 2005. 3:565–569.